This clinical trial studies cognitive function in men with prostate cancer treated with
androgen receptor directed therapies such as abiraterone acetate and enzalutamide. The
investigators use MRI imaging (non-invasive, non-contrast) to see whether there are changes
in brain structure or activity related to treatment that may be related to changes in
cognitive function. The investigators are also looking for genetic variations that might make
patients more or less sensitive to cognitive changes during treatment for prostate cancer.